The Pharmaceutical Market: Canada
|カナダの医薬品市場 The Pharmaceutical Market: Canada|
|出版日: 2013年01月31日||ページ情報: 英文||
当レポートでは、カナダの医薬品市場について、市場全体の動向と法規制、 医薬品流通チャネルなどを分析し、OTC医薬品、ジェネリック医薬品、 バイオ医薬品・バイオシミラーなどのセグメント別の動向、市場の機会と課題などを併せ、 概略下記の構成でお届けいたします。
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
Specialised intelligence on OTCs, generics, biologics and biosimilars.
Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
THE PHARMACEUTICAL MARKET: CANADA - REVIEW
The stable economic and political environment in Canada will help pharmaceutical companies to generate a consistent market growth in Q412. However, drugmakers will continue to face pricing pressure from the government and patent cliff effects in the country. Nevertheless, the epidemiological demands of an ageing population will counterbalance some of those pressures, even though we expect the generic drug market will significantly outperform its patented counterpart.
Headline Expenditure Projections Pharmaceuticals: CAD26.28bn (US$26.57bn) in 2011 to CAD26.64bn (US$25.87bn) in 2012; +1.4% growth in local currency terms and -2.7% growth in US dollar terms. Forecast slightly up from Q312 on account of macroeconomic factors. Healthcare: CAD181.47bn (US$183.47bn) in 2011 to CAD190.54bn (US$184.99bn) in 2012; +5.0% growth in local currency terms and +0.8% growth in US dollar terms. Forecast up slightly from Q312 due to macroeconomic factors. Medical Devices: CAD6.52bn (US$6.59bn) in 2011 to CAD6.78bn (US$6.58bn) in 2012; +3.9% growth in local currency terms and -0.2% growth in US dollar terms. Forecast the same as in Q312. Risk/Reward Rating: In BMI's Pharmaceutical and Healthcare Risk/Reward Ratings (RRRs) for Q412, Canada stays in second place in our regional matrix, which assesses 17 key markets in the Amercias. However, the average RRR score for the region decreased from 49.6 in Q312 to 49.2 in Q412 due to the worsening average industry rewards score.
The Canadian Pharmaceuticals & Healthcare Report features Espicom's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
Espicom's Canadian Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Canadian pharmaceutical and healthcare industry.
Benchmark Espicom's independent pharmaceutical and healthcare industry forecasts to test other views - a key input for successful budgeting and strategic business planning in the Canadian pharmaceutical and healthcare market.
Target business opportunities and risks in the pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Canada.
Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Espicom's forecast analysis, and taken together with Espicom's political, economic and business environment SWOTS, it gives a complete overview of market climate.
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.
Espicom Industry Forecasts
Forecasts to end-2016 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per '000 population), doctors (per '000 population), birth and mortality rate (per '000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of Espicom's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.